Seattle-based coffeehouse chain known for its signature roasts, light bites and WiFi availability.

During the past decade, Dokkyo Medical University Hospital conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 9 clinical trials were completed, i.e. on average, 39.1% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 8 clinical trials were completed. i.e. 53.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Dokkyo Medical University Hospital" #1 sponsor was "Shire" with 5 trials, followed by "Pfizer" with 4 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored, "Janssen Research & Development, LLC" with 3 trials sponsored and "Celgene" with 3 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dokkyo Medical University Hospital" #1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Guidant Corporation" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "Takeda Development Center Americas, Inc." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Dokkyo Medical University Hospital" are "Migraine" (6 trials), "Crohn's Disease" (4 trials), "Ulcerative Colitis" (3 trials), "Myelodysplastic Syndromes" (2 trials) and "Arrhythmias, Cardiac" (1 trials). Many other conditions were trialed in "Dokkyo Medical University Hospital" in a lesser frequency.

Most popular intervention types in "Dokkyo Medical University Hospital" are "Drug" (22 trials), "Other" (5 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Ontamalimab" (4 trials), "Eptinezumab" (2 trials), "Luspatercept" (2 trials) and "25 mg Ontamalimab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Dokkyo Medical University Hospital" are 24 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Dokkyo Medical University Hospital". undefined are not yet recruiting, 9 are recruiting, 3 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 8 completed trials in Dokkyo Medical University Hospital, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Dokkyo Medical University Hospital, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".